On May 1, 2025, Biogen Inc. reported first-quarter 2025 financial results, surpassing both profit and revenue expectations. Total revenue for the quarter increased by 6.1% year-over-year, reaching $2.43 billion. This growth was significantly supported by the company's emerging portfolio of new therapies.
Revenue from the four recent launch products collectively reached $200 million in Q1 2025, marking a 22% sequential increase from Q4 2024 and more than doubling from Q1 2024. The Rare Disease segment was a key contributor, with revenue increasing by 32.9% year-over-year to $563.3 million, driven by strong performance from SPINRAZA and the continued ramp-up of SKYCLARYS ($123.9 million) and QALSODY ($15.5 million).
Alzheimer's Collaboration revenue, primarily from LEQEMBI, also showed substantial growth, reaching $33.0 million in Q1 2025, a significant increase from $2.8 million in the prior-year period, with global end-market sales reported by Eisai at approximately $96 million. Conversely, the legacy multiple sclerosis franchise continued its expected decline, with revenue decreasing by 11.4% year-over-year to $953.0 million, primarily due to intense generic and biosimilar competition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.